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Abstract
Purpose: As genome-scale technologies begin to unravel the complexity of the equivalent tumors in
adults, we can attempt detailed characterization of high-grade gliomas in children, that have until recently
been lacking. Toward this end, we sought to validate and extend investigations of the differences between
pediatric and adult tumors.
Experimental Design: We carried out copy number profiling by array comparative genomic hybrid-
ization using a 32K bacterial artificial chromosome platform on 63 formalin-fixed paraffin-embedded
cases of high-grade glioma arising in children and young people (<23 years).
Results: The genomic profiles of these tumors could be subclassified into four categories: those with
stable genomes, which were associated with a better prognosis; those with aneuploid and those with high-
ly rearranged genomes; and those with an amplifier genotype, which had a significantly worse clinical
outcome. Independent of this was a clear segregation of cases with 1q gain (more common in children)
from those with concurrent 7 gain/10q loss (a defining feature of adults). Detailed mapping of all the
amplification and deletion events revealed numerous low-frequency amplifications, including IGF1R,
PDGFRB, PIK3CA, CDK6, CCND1, and CCNE1, and novel homozygous deletions encompassing un-
known genes, including those at 5q35, 10q25, and 22q13. Despite this, aberrations targeting the “core
signaling pathways” in adult glioblastomas are significantly underrepresented in the pediatric setting.
Conclusions: These data highlight that although there are overlaps in the genomic events driving glio-
magenesis of all ages, the pediatric disease harbors a distinct spectrum of copy number aberrations com-
pared with adults. Clin Cancer Res; 16(13); 3368–77. ©2010 AACR.
The use of genome-scale profiling techniques to identify
the key genetic aberrations underlying various tumor types
has led to fundamental discoveries about the drivers of on-
cogenesis, and provides the rationale for specific targeted
therapies in these lesions. Until recently, the application of
such studies to the fields of high-grade glioma specifically,
and childhood tumors in general, have lagged behind the
adult epithelial cancers. This is now rapidly changing, with
large screens of adult glioblastoma through collaborative
networks (1) or single institutions (2) joining an increa-
sing number of smaller independent studies (3–7) in com-
prehensively mapping the glioblastoma genome.
There are also beginning to emerge genomic studies spe-
cifically addressing childhood cancers, and there is moun-
ting evidence that the pediatric high-grade glioma genome
has certain key differences with that of histologically
similar adult tumors. An early study using metaphase
comparative genomic hybridization (CGH; ref. 8) high-
lighted distinct chromosomal changes in 23 childhood
cases, a result borne out in a later 10K single nucleotide
polymorphism (SNP) array study of a further 14 high-
grade tumors (9), and more recent studies of 18 pediatric
glioblastoma on Illumina 100K arrays (10), and 20 high-
grade tumors using molecular inversion probes (11). Most
recently, we participated in a collaborative effort to carry
out molecular profiling of 78 pediatric high-grade gliomas
by Affymetrix 500K SNP and U133 Plus2.0 expression ar-
rays (12). From all these studies, it seems clear that al-
though there are many large-scale chromosomal and
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specific genetic amplification/deletion events common to
tumors from patients of all ages, there are certain events
found at significantly different frequencies in pediatric ver-
sus adult lesions.
One of the most immediately apparent differences was
the high frequency of chromosome 1q gains and 16q losses,
and the lower frequency of (often concurrent) gain of chro-
mosome 7 and loss of 10q in childhood cases compared
with adults. Although there were numerous low-frequency
amplifications and deletions such asMYC/MYCN, CCND2,
KRAS, and CDKN2C, which seemed to show the pediatric
high-grade glioma genome to be similar to clinical secon-
dary adult glioblastomas (13, 14), a lack of IDH1mutations
in the childhood setting showed the distinct biological
pathways active during pathogenesis (12).
The most common amplification in the pediatric cases
was at 4q12, with shortest region of overlap (SRO) and ex-
pression analyses identifying the amplicon driver to be
PDGFRA (12). This was present in up to 17% of primary
pediatric glioblastoma, and 29% of diffuse intrinsic pon-
tine glioma, and was also found in 50% of cases of high-
grade glioma arising as a secondary malignancy after
cranio-spinal radiation (post-IR). Many cases without
PDGFRA amplification were still found to show overexpres-
sion of a specific PDGFRA-associated gene signature, which
was itself distinct from that observed in adult cases with the
4q12 amplification. Taken together, platelet-derived
growth factor (PDGF)-driven signaling seems to be pre-
ferentially activated in the majority of pediatric tumors, in
contrast to adults, where epidermal growth factor receptor
(EGFR) is implicated as the predominant target (12).
Although these studies are beginning to unravel the
key features of the pediatric high-grade glioma genome,
the total number of cases studied remains considerably
smaller than for adult tumors. This is of particular im-
portance given the lower frequency of the majority of
genetic aberrations detected in childhood cases. Valida-
ting these low-frequency events in independent cohorts
as being recurrent abnormalities, as well as the likely
identification of novel isolated copy number changes
will aid our understanding of the key pathways under-
lying the diversity of high-grade gliomas in children. To
this end we carried out an array CGH study of 63 cases
of pediatric high-grade glioma from formalin-fixed,
paraffin-embedded (FFPE) archival pathology specimens
on a 32K tiling-path bacterial artificial chromosome
(BAC) platform.
Materials and Methods
Samples and DNA extraction
High-grade glioma samples from 63 patients
(<23 years old) treated at the Royal Marsden Hospital
(RMH), Sutton, and the Newcastle Royal Infirmary,
United Kingdom, were obtained after approval by local
and multicenter ethical review committees. The collec-
tion consisted of 37 glioblastoma multiforme, 14 ana-
plastic astrocytomas, 4 anaplastic oligodendrogliomas,
4 diffuse intrinsic (brain stem) gliomas, 2 astroblas-
toma, 1 oligoastrocytoma, and 1 gliosarcoma. All cases
were archival FFPE tissues. The presence of tumor tissue
in these samples and the tumor type were verified on a
H&E-stained section independently by two neuropatho-
logists (DWE and SA-S). Nine of the cases were pre-
viously profiled from a frozen tumor specimen in the
collaborative SNP study (12). DNA was extracted using
the DNeasy Tissue Kit (Qiagen) according to the manu-
facturer's protocol and quantitated on a NanoDrop spec-
trophotometer (Thermo Scientific).
Array CGH
All raw and processed data have been deposited in
Array Express (http://www.ebi.ac.uk/microarray-as/ae/;
E-TABM-857). The array CGH platform used in this study
was constructed at the Breakthrough Breast Cancer
Research Centre and comprises 31,619 overlapping BAC
probes covering the human genome at an approximate
resolution of 50 kb (A-MEXP-1734). Hybridizations were
carried out as previously described (15) and slides were
scanned using an Axon 4000B scanner (Axon Ins-
truments) with images analyzed using Genepix Pro 4.1
software (Axon Instruments). The median localized
background slide signal for each clone was subtracted
and each clone Cy5/Cy3 ratio was normalized by local
regression (loess) against fluorescence intensity and
spatial location. Clones overlapping known copy number
variants were removed for statistical and visualization
purposes, but not for mapping of specific amplifications
Translational Relevance
Pediatric high-grade gliomas represent clinically
devastating and biologically understudied tumors of
the central nervous system. Little is known about the
key genomic alterations that arise in childhood cases,
nor of the specific differences between these and the
adult disease. We present the copy number profiling
of a large series of these rare tumors, and identify nu-
merous low-frequency events previously unreported in
pediatric high-grade glioma, including the potential
therapeutic target IGF1R. Tumors could be classified in-
to distinct genomic subtypes, with marked differences
in clinical outcome, and an idealized PDGFRAamp,
1q+, 16q-genotype was considerably enriched in pedi-
atric cases, in contrast to the EGFRamp, 7+, 10q- cases
more commonly associated with adults. We further
highlight the importance of platelet-derived growth fac-
tor (PDGF) signaling in this context, through the most
commonly observed genomic amplification of
PDGFRA, as well as a unique amplification of PDGFRB,
providing strong rationale for clinically targeting this
pathway in children with this disease.
Array CGH of Pediatric High-Grade Glioma
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and deletions, which was done according to the March
2006 build of the human genome sequence (hg18).
Data analysis
All data transformation and statistical analysis were car-
ried out in R 2.9.0 (http://www.r-project.org/) and Bio-
Conductor 2.4 (http://www.bioconductor.org/), making
extensive use of modified versions of the package aCGH
in particular (15). For identification of DNA copy number
alterations, data were smoothed using a local polynomial
adaptive weights procedure for regression problems with
additive errors, with thresholds for assigning “gain” and
“loss” set at 0.1 (3 × SD of control hybridizations). For vi-
sualization purposes, the processed log2 ratios were co-
lored green (gain) or red (loss) after segmentation and
copy number determination.
To assess the significance of the genomic alterations,
we applied an algorithm similar to those previously des-
cribed, namely, Genomic Identification of Significant
Targets in Cancer (GISTIC; ref. 13) and Genome Topog-
raphy Scanning (GTS; ref. 16), taking into account the
frequency, amplitude, and focality of the observed am-
plifications (log2 ratio >1.0) and deletions (log2 ratio
<−0.75). This was calculated as the product of the abso-
lute log2 ratio, the number of clones in each segment,
and the frequency within the entire cohort, scaled to
the absolute maximum for amplifications/deletions sep-
arately, and overplotted on the frequency histogram for
gains and losses described above.
Fluorescent in situ hybridization
Fluorescent in situ hybridization (FISH) analysis was car-
ried out on FFPE sections as previously described (17).
Probes directed against MYCN (pool of clones RP11-
1183P10, RP11-674F13 and RP11-754G14), PIK3CA
(RP11-4B14, RP11-642A13, RP11-379M20), PDGFRA
(RP11-819D11, RP11-58C6), SKP2 (RP11-749P08, CTD-
2010F22), PDGFRB (RP11-211F05, RP11-21I20), MYC
(RP11-440N18, RP11-237F24, CTD-2034C18), CDK4
(RP11-66N19, RP11-277A02, RP11-672O16), MDM2
(RP11-611O02, RP13-618A08, CTD-2067J14), and IGF1R
(CTD-2015I17, RP11-203H14, RP11-189B22) were la-
beled with Cy3 (GE Healthcare), whereas chromosome-
specific control probes at loci of no copy number change
were labeled with fluorescein (GE Healthcare). Hybridized
preparations were counterstained with 4′, 6-diamidino-2-
phenylindole in antifade (Vector Laboratories Inc.).
Images were captured using a cooled charge-coupled de-
vice camera (Photometrics).
Statistics
All statistical tests were done in R2.9.0. Correlations be-
tween categorical values were done using the χ2 and Fish-
er's exact tests. Correlations between continuous variables
were done using Student's t test or the Mann-Whitney U
test. Cumulative survival probabilities were calculated
using the Kaplan-Meier method on uniformly treated pa-
tients within our cohort from the same institution (RMH),
with differences between survival rates analyzed with the
log-rank test. Important prognostic information (inclu-
ding extent of resection, Karnofsky performance score)
was not available for all cases in this retrospective study,
so multivariate analysis could not be done. All tests were
two-tailed, with a confidence interval of 95%. P values of
<0.05 were considered statistically significant.
Results
Distinct patterns of copy number change in the
pediatric high-grade glioma genome
Previously we utilized whole genome amplification
strategies for array CGH studies of tumors extracted from
FFPE specimens (18). In this study, however, we were able
to utilize a cohort of samples for which sufficient material
was available to avoid the previous approach. We were
able to generate high-quality copy number profiles from
an unselected series of 63 pediatric high-grade gliomas
using 32K tiling-path BAC arrays from which the tumor
cell purity could be verified as >90% without the need
for additional steps.
We observed a mean number of large-scale (whole chro-
mosome or chromosomal arms) gains and losses of
5.8 per sample (median, 4; range, 0-22), with more losses
(mean, 3.5; median, 3; range, 0-14) than gains (mean, 2.3;
median, 2; range, 0-11). There was a further mean of
1.8 focal amplifications/deletions per sample (median,
1; range, 0-11), again with a slightly increased number
of deletions (mean, 1.0; median, 0; range, 0-8) compared
with amplifications (mean, 0.8; median, 0; range, 0-4).
The list of observed alterations is given for the full dataset
in Supplementary Table S1.
We were able to subtype the samples into four groups
based upon the pattern of their genomic profiles. First
was a group of tumors that had a very stable genome,
with few (<3), low-level, focal changes. This subtype
comprised 13 of 63 (20.6%) cases, and included 8 tu-
mors (12.7%) that harbored no detectable copy number
alterations on our 32K BAC platform (Fig. 1A). The se-
cond type contained only large, single copy alterations
involving whole chromosomes or chromosomal arms, re-
sulting in aneuploidy in the absence of any high-level
amplifications in 22 of 63 (34.9%) cases, the largest sub-
group we observed (Fig. 1B). The third type harbored nu-
merous, low-level, intrachromosomal breaks resulting in
multiple gains and losses and a highly rearranged ge-
nome. This group was also defined for this purpose by
exclusion of cases with bona fide amplicons, and com-
prised 11 of 63 (17.5%) of the cohort (Fig. 1C). Finally,
we considered those tumors with single or multiple high-
level (log2 ratio >1.0) amplifications, regardless of the
genomic background, as belonging to the fourth, “ampli-
fier” subtype. This group consisted of 17 of 63 (27.0%)
of cases (Fig. 1D).
There were no significant correlations between genomic
subtype and WHO grade or histology (P > 0.05, Fisher's
exact test), with glioblastomas, anaplastic astrocytomas,
Bax et al.
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and anaplastic oligodendrogliomas spread across all sub-
types. Of note, there were no “stable” genomic cases
among the series of five patients that were treated for a
previous malignancy by cranio-spinal radiation (post-IR;
Supplementary Table S1). There was also no association
of copy number profiles with age at diagnosis (P > 0.05,
Mann-Whitney U test), although the amplifier group did
not include any infant tumors (<3 years). However, when
we investigated the overall survival of the patients treated
at a single institution (RMH), we detected significant dif-
ferences by retrospective univariate analysis in the clinical
outcome of cases according to the genomic profile of the
tumor. The stable genome cases showed a trend towards
better prognosis when compared with all other cases
(P = 0.0755, log-rank test), whereas the samples with an
amplifier genome had a significantly shorter time to death
Fig. 1. Pediatric high-grade gliomas comprise different subtypes of copy number profiles. Sample genome plots are given for stable (A), aneuploid
(B), rearranged (C), and amplifier (D) genomes within our sample cohort. Log2 ratios for each clone (Y-axis) are plotted according to chromosomal
location (X-axis). Vertical lines, centromeres; green points, gains; red points, losses.
Fig. 2. Genomic subtypes of pediatric
high-grade glioma have prognostic
relevance. Kaplan-Meier plot for overall
survival of pediatric high-grade gliomas
treated at a single institution stratified
according to genomic subtype. The stable
genome cases showed a trend towards
better prognosis when compared with all
other cases (P = 0.0755, log-rank test),
whereas the samples with an amplifier
genome had a significantly shorter time
to death (P = 0.00214, log-rank test).
Array CGH of Pediatric High-Grade Glioma
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(P = 0.00214, log-rank test; Fig. 2). The aneuploid and re-
arranged cases fell in between, and were representative of
the survival characteristics of the cohort as a whole,
suggesting that they may need to be considered together
as falling between the extremes of the other two groups.
One of the defining features of pediatric high-grade gli-
oma is the frequent gain of chromosome 1q (12 of 63, or
19.0%, versus 17 of 189, or 9.0%, of adult cases; ref. 1; P =
0.039, Fisher's exact test) and loss of 16q (11 of 63, or
17.5%, versus 14 of 189, of 7.4%; P = 0.028, Fisher's exact
test); in contrast to adult glioblastoma cases, in which gains
of chromosome 7 (12 of 63, or 19.0%, versus 140 of 189, or
74.1%; P < 0.0001, Fisher's exact test) and losses of 10q (10
of 63, or 15.9%, versus 152 of 189, or 80.4%; P < 0.0001,
Fisher's exact test) predominate. In our FFPE cohort, we no-
ticed a clear distinction of 1q gain cases from those with
concurrent 7 gain/10q loss (7+/10q-, 8 of 63, or 12.7%),
with only a single case harboring both abnormalities. Nei-
ther event was significantly associated with any clinicopath-
ologic parameters, although there was a trend towards
shorter survival in the 1q+ cases (P = 0.0865, log-rank test).
Neither abnormality was seen in any infant cases.
Mapping of focal amplifications and deletions to
known oncogenes and novel loci
As we had with large-scale alterations, we observed nu-
merous focal amplifications and deletions. In summary,
we identified 47 unique amplification and 32 unique de-
letions. All these events are detailed in full in Supplemen-
tary Table S2 (amplifications) and Supplementary
Table S3 (deletions).
The most common amplicon was at 4q12 (10 of 63, or
15.9%), and deletion at 9p21 (10 of 63, or 15.9%, consis-
ting of 8 homozygous, 2 hemizygous). Mapping the SRO
in these cases narrowed these regions specifically to
PDGFRA and CDKN2A, respectively, confirming the initial
observations that these are by far the most common am-
plifications/deletions in pediatric high-grade glioma (12).
Other common events included amplification ofMYCN at
2p24 (3 of 63, or 4.7%) or MYC at 8q24 (2 of 63, or
3.2%), together giving a frequency of 7.9% (5 of 63) of
cases with genomic MYC family dysregulation; and 3
of 63 (4.7%) EGFR amplification at 7p12 – a lower fre-
quency than observed in our recent chromogenic in situ
hybridization study of a larger cohort of which this series
is a subset, reflecting the focal nature of the amplification
event in a small number of tumors identified by molecular
pathology (19).
For the remaining aberrations, we highlighted the SROs
where they were found to be recurrent. However, as most
were present only in a single case, and we were unable to
narrow down gained/lost regions, the result was that we
identified a total of 1,026 amplified and 1,243 deleted
genes across our series. To facilitate the identification of
key oncogenic events in pediatric high-grade glioma, we
sought to assign significance to the genomic aberrations
we observed. Inspired by algorithms such as GISTIC (13)
and GTS (16), we developed a simple measure based upon
three key features of our data for each clone on the array:
(a) frequency of high-level amplification/homozygous de-
letion, (b) absolute magnitude of the change, and (c) fo-
cality of the segmented copy number change. This
amplitude/focality measure was then scaled to the maxi-
mum and minimum for amplifications/deletions, respec-
tively, and plotted over the frequency of low-level gains
and losses on the same histogram (Fig. 3).
As well as PDGFRA (the highest scoring gene) and
CDKN2A, this analysis highlighted the importance of seve-
ral known oncogenes, amplified at low frequency in our
series, but at high magnitude, and in a focally restricted
Fig. 3. Summary and significance of genomic aberrations in pediatric high-grade glioma. The proportion of tumors in which each clone is gained or lost is
plotted in grey (Y-axis) for each BAC clone according to genomic location (X-axis). A measure of the frequency, amplitude, and focality of high-level
events was calculated for each affected clone and was overplotted for amplifications (green) and deletions (red), scaled to the absolute maximum for each.
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manner. These included PIK3CA (3q26), CDK6 (7q21),
and CDK4 (12q14), the first two previously reported in
adult glioblastoma, but not in pediatric cases, and present
here in a single case. We also identified amplifications of
two additional receptor tyrosine kinases: IGF1R at 15q26
(Fig. 4A) and PDGFRB at 5q33 (Fig. 4B). Such an ap-
proach further highlighted the potential significance of
known deletions targeting PARK2 at 6q6 and MGMT,
PTPRE, and others at 10q26, as well as unique events for
which the candidate gene is unknown at 10q25 (Fig. 4C)
and 11q14 (Fig. 4D).
We were able to validate nine of these lower-frequency
amplification events by carrying out FISH on our FFPE
sections using specific probes against MYCN, PIK3CA,
PDGFRA, SKP2, PDGFRB, MYC, CDK4, MDM2, and
IGF1R (Fig. 5).
Glioblastoma core signaling pathways are not
commonly activated by copy number changes in
pediatric patients
One of the most important findings from recent large-
scale genomic profiling studies of adult glioblastoma was
the identification of three core signaling pathways that
were abrogated by amplification, deletion, and/ormutations
of key genes in the vast majority of cases. Considering
only the copy number data from these studies, 59%,
70%, and 66% of cases were found to have at least one
genetic event targeting the receptor tyrosine kinase/
phosphoinositide 3-kinase (RTK/PI3K), p53, or RB
pathways, respectively (1, 2).
We mapped the copy number changes in our pediatric
cases to the same pathways, which included many of the
genes described above, as well as others described in adult
Fig. 4. Novel low-frequency amplifications and fine-mapping focal deletions in pediatric high-grade glioma. Chromosome plots for chromosome 15,
targeting IGF1R (A); chromosome 5, targeting PDGFRB/CSF1R (B); chromosome 10, mapping a deletion at 10q25.2-q25.3 (C); and chromosome 11,
resolving a deletion at 11q14 to ODZ4 and hsa-mir-708 (D). Log2 ratios for each clone are plotted (Y-axis) for each BAC clone according to location (X-axis)
along the length of the chromosome, with genes and microRNA within the minimal regions plotted underneath according to positional information from
the UCSC Genome Browser (hg18).
Array CGH of Pediatric High-Grade Glioma
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glioblastoma, including MET, KRAS, and AKT2 (RTK/
PI3K), MDM2 (p53), and CCND2 (RB). Despite this, we
observed a significantly lower frequency of pathway dysre-
gulation compared with that reported in adults: 16 of 63
(25%) RTK/PI3K, 12 of 63 (19%) p53, and 14 of 63
(22%) RB (all P < 0.0001, Fisher's exact test; Fig. 6). Even
after removing the stable genome subtype from this anal-
ysis, it is apparent that pediatric tumors show targeting of
these core pathways by copy number alterations in less
than half as many instances than in adults.
To explorewhether other canonical pathwaysmaybe acti-
vatedbythismechanismpreferentially inchildhoodtumors,
we mapped amplified/deleted genes in those tumors with-
out core pathway targeting via GenMAPP. Although there
were isolated cases with clear genomic events linked to
activationof theSonicHedgehog(GLI2amplification,HHIP
deletion) and Notch (DLL3 amplification, DLK1 deletion)
pathway activation, there was no consistently targeted path-
way in these cases, nor was there specific enrichment of any
additional pathway across the entire cohort.
Discussion
We were previously part of a collaborative study setting
out to comprehensively map the copy number alterations
present in the pediatric high-grade glioma genome, in
which we used Affymetrix 500K SNP arrays on a series of
78 cases available as frozen tumor samples (12). Those data
revealed an overlapping, but distinct, underlying molecular
genetics of the childhood disease when compared with re-
cent large-scale genomic analyses of adult high-grade glio-
ma (1, 2). Along with the common amplification/deletion
targets of PDGFRA and CDKN2A/B, there were numerous
low-frequency events targeting both well-recognized
Fig. 5. FISH validation of low-frequency amplifications in pediatric high-grade glioma. Specific probes forMYCN, PIK3CA, PDGFRA, SKP2, PDGFRB, MYC,
CDK4, MDM2, and IGF1R were labeled with Cy3 (red) and cohybridized to interphase nuclei on FFPE specimens with chromosome-specific control
probes labeled with fluoroscein.
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oncogenes and novel loci. The present study had three pur-
poses: (a) to validate the high-frequency events in an inde-
pendent set of samples, analyzed on an independent
microarray platform; (b) to extend the sample set to provide
evidence of recurrence of the low-frequency events previ-
ously reported; and (c) to identify novel low-frequency
events, which by their nature may have been missed in
the earlier study.
The most frequent focal events were PDGFRA amplifica-
tion andCDKN2A/B deletion, and themost common large-
scale gains and losses included chromosomes 1q and 16q,
respectively. The PDGFRAamp, 1q+, 16q- events were signifi-
cantly more common in the childhood setting (10, 11, 20),
although it is important to note that they are present in a
proportion of adult tumors. Similarly, we observed a group
of tumors in our cohort containing aberrations more com-
monly associated with the adult disease, namely EGFRamp,
7+, 10q-, albeit at significantly reduced frequencies. That
they tended towards exclusivity suggests they represent
archetypes for different ends of the spectrum of the disease.
One of the most intriguing differences observed in the
pediatric setting was the presence of a proportion of cases
of high-grade tumors with very few, or even no detectable
copy number alterations. This was true on both BAC
Fig. 6. Glioblastoma core signaling pathways are dysregulated by copy number changes less frequently in pediatric than in adult tumors. Signaling pathway
heatmap of interactions defined by the cancer genome atlas (1). Red, genes with amplifications; blue, genes with focal deletion. The overall
frequency of copy number alteration in pediatric high-grade glioma for each pathway is listed, and is significantly lower than in adults (25% RTK/PI3K,
19% p53, and 22% RB versus 59%, 70%, and 66% for adult glioblastoma, respectively).
Array CGH of Pediatric High-Grade Glioma
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(approximately 32,000 probes, 100 kb resolution) and
SNP (approximately 500,000 probes, 6 kb resolution)
platforms (12), and is in direct contrast to data from adult
tumors (1, 2). This stable genomic profile is independent
of histologic grade or type, and seems to convey an im-
proved survival in patients with high-grade glioma, in con-
trast to those patients with an amplifier genomic profile,
who do significantly worse.
Another of the defining features of the pediatric high-
grade glioma genome is the numerous low-frequency am-
plifications and deletions present only in isolated cases in
any given study. By nearly doubling the number of these
rare tumors for which we have genomic data, we have been
able to ascertain aberrations as recurrent across 132 cases.
These include amplifications of known oncogenes within
the core signaling pathways described in adult glioblasto-
ma, such as CDK6 (10),MET, and CCND2, as well as novel
targets. These include ID2 at 2p25, previously found in as-
sociation with theMYCN amplicon at 2p24, possibly part of
a single event, identified here as an independent target in its
own right. ID2 is a helix-loop-helix transcription factor that
has previously been shown to be widely expressed in astro-
cytic tumors (21, 22), and may play a role in negatively reg-
ulating cell differentiation and promoting cell survival (23,
24). Another amplicon at 17q22 was also confirmed in the
FFPE series, with a SRO analysis identifying RNF43 as the
most likely target. RNF43 is a ubiquitin ligase that promotes
cell growth and is upregulated in colon cancer (25, 26), but
has not previously been implicated in gliomagenesis.
Homozygous deletions now apparent as recurrent
lesions include those at 14q32, encompassing a large
number of microRNAs, as well as the gene DLK1. DLK1
is a δ-like homolog that acts to inhibit Notch signaling
through specific binding interactions with the receptor
(27), and may play diverse roles in cellular transformation
and differentiation (28). Although we have now observed
two cases of homozygous deletion, other mechanisms of
downregulation may be active, as DLK1 is present at an
imprinted locus, with increased methylation upstream of
GTL2 leading to reduced expression in other tumor types
(29). Other deletions may have a more complicated role
in gliomagenesis such as those on chromosome 16q. The
SNP study identified a large deletion in a single tumor that
is present as two separate events at 16q12 and 16q21 in
two independent cases here, targeting numerous candi-
dates including clusters of Iroquois homeobox genes, me-
tallothioneins, and coiled-coil domain containing genes.
By contrast, a homozygous deletion observed in the pres-
ent study overlaps two independent loci previously
reported at 11q14 to target a single microRNA, hsa-mir-
708, and a single gene, ODZ4. Although little seems
known about mir-708, the odd Oz/ten-m homolog 4 is
expressed in the developing and adult central nervous sys-
tem, and seems to act as an important transcriptional reg-
ulator associated with neurodevelopment (30, 31).
Finally, we were also able to identify several novel ampli-
fications and deletions, the significance ofmany of which is
not yet clear. There were some genes identified that were
also present in adult glioblastoma studieswhichhadnot pre-
viously been reported in pediatric high-grade glioma, such as
AKT2, CCNE1, GLI2, MDM2, PARK2, and PIK3CA. There
were other previously unreported genes that may be associ-
ated with specific glioblastoma- related signaling pathways
such as AKTIP (16q12), anAkt-interactingprotein that acts as
an activator of the PI3K pathway (32), and PIK3C3 (18q12),
also known as Vps34, a member of the PI3K family associat-
ed with autophagy (33). There were numerous others with
potential functional relevance unknown.
We also noted rare amplifications at receptor tyrosine
kinases considered less likely to be driven by copy number
gain. Firstly was a very high level gain of IGF1R at 15q26
(11). Insulin-like growth factor (IGF) signaling has previ-
ously been implicated in gliomagenesis, primarily on the
basis of high levels of the ligand IGF2 in glioblastoma spe-
cimens (34). The growth-promoting effects of IGF2 that
were shown were mediated via IGF1R and the PI3K regu-
latory subunit PIK3R3. Of particular relevance to the child-
hood setting was the observation of a mutual exclusivity
between IGF2-associated tumors and EGFR-driven cases,
suggesting that the IGF pathway may play a prominent
role in pediatric tumors, possibly in concert with PDGF re-
ceptor (PDGFR)-related signaling.
Secondly was an amplicon at 5q33 which included
PDGFRB (and another receptor tyrosine kinase CSF1R).
Given the clear importance of PDGFR signaling on pedi-
atric high-grade gliomas, it is perhaps unsurprising that
there may be multiple mechanisms active in driving
tumorigenesis through a common pathway. To this end,
we also observed recurrent amplification of the ligand
PDGFB (22q13) in the previous SNP study (12), and here
further observed focal copy number gain at 7p22 encom-
passing PDGFA. That these unique genomic events have
thus far been found to be restricted to pediatric tumors
adds further evidence to a distinct underlying genetics
driving archetypal high-grade gliomas in children, one
that is largely PDGF-driven, and forms a discrete pole
within the diversity of glioma biology. Understanding
the most appropriate ways of efficaciously targeting these
pathways in the most appropriate patient populations
will hopefully overcome the disappointing early-phase
clinical trials observed thus far with PDGFR inhibitors.
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